Literature DB >> 11672543

Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus détente.

C A Benedict1, T A Banks, L Senderowicz, M Ko, W J Britt, A Angulo, P Ghazal, C F Ware.   

Abstract

Tumor necrosis factor (TNF)-related cytokines regulate cell death and survival and provide strong selective pressures for viruses, such as cytomegalovirus (CMV), to evolve counterstrategies in order to persist in immune-competent hosts. Signaling by the lymphotoxin (LT)-beta receptor or TNF receptor-1, but not Fas or TRAIL receptors, inhibits the cytopathicity and replication of human CMV by a nonapoptotic, reversible process that requires nuclear factor kappa B (NF-kappa B)-dependent induction of interferon-beta (IFN-beta). Efficient induction of IFN-beta requires virus infection and LT signaling, demonstrating the need for both host and viral factors in the curtailment of viral replication without cellular elimination. LT alpha-deficient mice and LT beta R-Fc transgenic mice were profoundly susceptible to murine CMV infection. Together, these results reveal an essential and conserved role for LTs in establishing host defense to CMV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672543     DOI: 10.1016/s1074-7613(01)00222-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  43 in total

1.  A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT.

Authors:  Jennifer L Gommerman; Keith Giza; Stuart Perper; Irene Sizing; Apinya Ngam-Ek; Cheryl Nickerson-Nutter; Jeffrey L Browning
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

2.  Postinternalization inhibition of adenovirus gene expression and infectious virus production in human T-cell lines.

Authors:  Adrienne L McNees; Jeff A Mahr; David Ornelles; Linda R Gooding
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 3.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

4.  Regulation of the transcription and replication cycle of human cytomegalovirus is insensitive to genetic elimination of the cognate NF-kappaB binding sites in the enhancer.

Authors:  Montse Gustems; Eva Borst; Chris A Benedict; Carmen Pérez; Martin Messerle; Peter Ghazal; Ana Angulo
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway.

Authors:  Timothy C Cheung; Ian R Humphreys; Karen G Potter; Paula S Norris; Heather M Shumway; Bonnie R Tran; Ginelle Patterson; Rochelle Jean-Jacques; Miri Yoon; Patricia G Spear; Kenneth M Murphy; Nell S Lurain; Chris A Benedict; Carl F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

Review 6.  Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway.

Authors:  Thomas W Spahn; Hans-Pietro Eugster; Adriano Fontana; Wolfram Domschke; Torsten Kucharzik
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 7.  Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways.

Authors:  Carl F Ware
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

8.  Modulation of the NFκb Signalling Pathway by Human Cytomegalovirus.

Authors:  Meaghan H Hancock; Jay A Nelson
Journal:  Virology (Hyderabad)       Date:  2017-07-31

Review 9.  Lymphotoxin in physiology of lymphoid tissues - Implication for antiviral defense.

Authors:  Ekaterina P Koroleva; Yang-Xin Fu; Alexei V Tumanov
Journal:  Cytokine       Date:  2016-09-09       Impact factor: 3.861

10.  Lymphoid-tissue stromal cells coordinate innate defense to cytomegalovirus.

Authors:  Shilpi Verma; Qiao Wang; Grzegorz Chodaczek; Chris A Benedict
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.